Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put
Grifols, S.A. (stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: GRFS Quick Quote GRFS - Free Report) PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Grifols has a trailing twelve months PE ratio of 15.13, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 25.93. If we focus on the long-term PE trend, Grifols’ current PE level puts it below its midpoint over the past five years.
Further, the stock’s PE compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 25.2. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Grifols has a forward PE ratio (price relative to this year’s earnings) of just 13.98, so it is fair to say that a slightly more value-oriented path may be ahead for Grifols stock in the near term too.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Grifols has a P/S ratio of about 2.21. This is lower than the S&P 500 average, which comes in at 4.55 right now. Also, as we can see in the chart below, this is below the highs for this stock in particular over the past few years.
If anything, GRFS is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate Grifols currently has a Zacks Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Grifols a solid choice for value investors.
What About the Stock Overall?
Though Grifols might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of A and a Momentum Score of D. This gives GRFS a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores
here >> )
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current year has seen one estimate go higher in the past sixty days compared to one lower, while the full year 2021 estimate has seen two downward revision compared to no upward in the same time period.
This has had a suitable impact on the consensus estimate though as the current year consensus estimate has improved by 19.7% in the past two months, while the full year 2021 estimate has fallen by 1.4%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
Grifols is an inspired choice for value investors, as it is hard to beat its incredible line up of statistics on this front.
However, with a sluggish industry rank (among bottom 28% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the Zacks Medical – Drugs industry has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>